v3.26.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 24, 2026
Jun. 30, 2025
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Dec. 31, 2025      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2025      
Current Fiscal Year End Date --12-31      
Entity File Number 001-38325      
Entity Registrant Name enVVeno Medical Corporation      
Entity Central Index Key 0001661053      
Entity Tax Identification Number 33-0936180      
Entity Incorporation, State or Country Code DE      
Entity Address, Address Line One 70 Doppler      
Entity Address, City or Town Irvine      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 92618      
City Area Code (949)      
Local Phone Number 261-2900      
Title of 12(b) Security Common Stock, $0.00001 par value      
Trading Symbol NVNO      
Security Exchange Name NASDAQ      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
Entity Shell Company false      
Entity Public Float       $ 76.1
Entity Common Stock, Shares Outstanding     655,521  
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Auditor Firm ID 199 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheet of enVVeno Medical Corporation (the “Company”) as of December 31, 2025, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the year ended December 31, 2025 and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

 

We also have audited the adjustment to the 2024 consolidated financial statements for the reverse stock split described in Note 1. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the 2024 consolidated financial statements of the Company other than with respect to the reverse stock split and, accordingly, we do not express an opinion or any other form of assurance on the 2024 financial statements taken as a whole.

  		     
Auditor Name CBIZ CPAs P.C. Marcum LLP    
Auditor Location New York, NY New York, NY